Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (NCT01436968)
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak or control arm at a 2:1 ratio. Both arms receive standard external beam radiation therapy. Short-term androgen deprivation therapy may be given but is not required.
Who can join: Review the eligibility criteria below.
Location: Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (73 Sites)
Showing the first 25 of 73 sites.
- Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
- Arizona Urology Specialists — Glendale, Arizona
- Arizona Oncology Services Foundation — Multiple Locations, Arizona
- Arizona Center for Cancer Care - Peoria — Peoria, Arizona
- Arizona Center for Cancer Care - Deer Valley — Phoenix, Arizona
- Arizona Center for Cancer Care - Osborne — Scottsdale, Arizona
- Arizona Center for Cancer Care - Shea — Scottsdale, Arizona
- Arizona Center for Cancer Care - Surprise — Surprise, Arizona
- Southern Arizona VA Health Care System — Tucson, Arizona
- VA Northern California Health Care System — Mather, California
- Precision Radiation Oncology — Tustin, California
- Valley View Hospital — Glenwood Springs, Colorado
- Colorado Clinical Research — Lakewood, Colorado
- Advanced Urology — Parker, Colorado
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- 21st Century Oncology — Fort Lauderdale, Florida
- 21st Century Oncology — Lakewood Rch, Florida
- 21st Century Oncology — Naples, Florida
- 21st Century Oncology — Plantation, Florida
- Clinical Research Center of Florida — Pompano Beach, Florida
- James A. Haley Veteran's Hospital — Tampa, Florida
- Florida Urology Partners — Tampa, Florida
- Jesse Brown VA Medical Center — Chicago, Illinois
- The University of Chicago — Chicago, Illinois
- Silver Cross Hospital — New Lenox, Illinois
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.